Oncology/Hematology
At a glance...
Oncology
Hematology
|
Oncology “In the age of novel therapies, what defines high-risk multiple myeloma?” (review) “Clinical experience with arsenic trioxide in cancer” (review) “A phase-2 study of arsenic trioxide in patients with refractory or relapsed multiple myeloma” (clinical trial) “Lymphomas after solid organ transplantation” (registry-based study) “Myelodysplastic syndromes: from pathogenesis and prognosis to treatment” (review) “New opportunities for the management of cancer-related bone complications” (CME review) “Management of prostate cancer-related bone complications" (CME review) “Long-term follow–up of diclofenac trial-3% in 2.5% hyaluronic acid gel for actinic keratosis: 1-year evaluation” (clinical trial) “Tanespimycin pharmacokinetics: a randomized, dose-escalating, crossover phase 1 study" (clinical trial) “Elotuzumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: a phase I study” (clinical trial) “Corticosteroids as prophylaxis for infusion-related adverse events in patients with acute myeloid leukemia treated with Mylotarg™ (gemtuzumab ozogamicin)” (clinical trial) “Phase I trial of the oral farnesyl transferase inhibitor sarasar: a Pediatric Brain Tumor Consortium Study” (poster) “Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: a phase 1/2 study” (poster) “Diclofenac sodium 3% gel for the treatment of actinic keratosis: review of 10+ years of clinical evidence” (poster) “Long-term effectiveness of Solaraze® gel (diclofenac sodium-3%) for the treatment of actinic keratosis: results at 1-year follow-up” (poster) “Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: updated results of a phase 1 study” (meeting abstract) “Non-Hodgkin’s lymphoma: current management” (focus on G-CSF and monoclonal antibodies (slide kit with notes) “Optimizing antitumor therapy in non-Hodgkin’s lymphoma with granulocyte-macrophage colony stimulating factor (slide kit with notes) “Cutaneous T-cell lymphoma overview” (slide kit with notes) “Melanoma disease background” (slide kit with notes) Solaraze gel and the long-term management of patients with actinic keratosis (branded slide kit with notes) Practical Decision Making: Enhancing Outcomes in Hematologic Malignancies (CME monograph) “The cytogenetics of MDS” (CME newsletter) “Global management of MDS” (CME newsletter) “New treatment strategies in MDS: noncytokine hematopoietic promoters” (CME newsletter) “Clinical experience of lenolidomide in relapsed/refractory multiple myeloma” (CME newsletter) “Current options for the treatment of myelodysplastic syndromes in Europe” (CME newsletter) “Hemorrhagic and thrombotic complications of acute promyelocytic leukemia” (workshop report) AMCP dossier for letrozole (Femara) (clinical section) Advisory board meeting slides---alkylating agent for AML Hematology AMCP dossier for deferasirox (HE/OR section) “Risk factors for chronic kidney disease and its related complications” (CME report) “The importance of early and consistent treatment of anemia” (CME report) "Economic considerations in the management of anemia” (CME report) “New advances in the management of anemia” (CME report) “Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura” (clinical trial) “Long-term open-label treatment with eltrombopag in japanese patients with previously treated chronic immune thrombocytopenia” (clinical trial) “Effect of eltrombopag on platelet response, bleeding and reduction in concomitant ITP medications in adults with chronic idiopathic (immune) thrombocytopenic purpura and baseline platelets ≤15,000/µl” (poster) “Effect of individualized eltrombopag dosing on platelet response in patients with chronic idiopathic (immune) thrombocytopenic purpura” (poster) “Long-term safety and efficacy of eltrombopag olamine in adults with idiopathic thrombocytopenic purpura in the eltrombopag extended dosing” (EXTEND) Study (meeting abstract) “Mortality during clinical studies of eltrombopag in patients with immune thrombocytopenic purpura” (meeting abstract) “Prolonged response to eltrombopag in patients with chronic immune thrombocytopenic purpura” (meeting abstract) |
Back to Areas of Expertise